Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

详细信息    查看全文

• 作者：Selma Ugurel¹ ; Jü ; rgen C. Becker¹ ; ² ; ^{j.becker@dkfz.de}
• 刊名：Journal of Investigative Dermatology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：137
• 期：2
• 页码：277-279
• 全文大小：361 K
• 卷排序：137

文摘

There is increasing evidence that certain kinase inhibitors are able to foster two strategies, i.e. inhibition of oncogenic activated molecular pathways and modulation of immunological processes. In this respect, the study of Tazzari et al. is of great interest because it shows both effects for the kinase inhibitor imatinib in dermatofibrosarcoma protuberans.